Durvalumab combined with ceralasertib showed promising clinical benefits in immunotherapy-refractory of non-small cell lung cancer, particularly in patients with Ataxia-Telangiectasia Mutated (ATM) alterations (43). This evidence concerns the gene ATM and non-small cell lung carcinoma.